Higher solvency than 95% of companies in human health. Sector median 59.4% · 2,816 companies.
Checked score
Checked score
The higher the Checked score (0 to 100), the smaller the chance that the company goes bankrupt within twelve months. That chance sets the band, from Critical to Excellent, and within the band how the company does against its sector peers counts too. With a low score, agree a shorter payment term, an advance or security.
XXVisible after signing in
HiddenVisible after signing in
Bankruptcy probability within 12 months
Bankruptcy probability
It is the chance that the company goes bankrupt within twelve months, estimated from the registers, the annual accounts and the Belgian Official Gazette. At 0.2%, about 2 in 1,000 comparable companies go bankrupt. The higher it is, the shorter the payment term to agree.
XXVisible after signing in
Financial strength
Financial strength
Financial strength measures the balance sheet and the results with three figures out of 100 from the latest annual accounts: solvency, liquidity and profitability. It does not directly set the Checked score's band. How the company does against its sector peers on these and on growth does count for its place within the band.
XXVisible after signing in
XXVisible after signing in
XXVisible after signing in
Score breakdown
Visible after signing inVisible after signing in
Comparable companies, two years later
In July 2024, 14,774 companies had the same profile as CLINIPHAR has now. Each dot stands for 37 companies, two years later.
96.1%
were still trading
3.5%
stopped another way
0.2%
went bankrupt
Small
20 years or older
solvency 30% or more
a profit under 5% of the balance sheet
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,962 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
The companies in ten equal groups, from the lowest to the highest expected share
Group
Expected
Actual
1
0.2%
0.2%
2
0.3%
0.5%
3
0.5%
0.6%
4
0.7%
0.8%
5
0.9%
0.9%
6
1.3%
1.5%
7
1.6%
1.8%
8
1.8%
1.8%
9
2.9%
3.1%
10
5.6%
6.1%
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 14,774 companies, not a prediction for CLINIPHAR. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit verdict
The credit verdict says how much credit you can give the company on open account. “Acceptable” means normal terms, “With conditions” means limiting the amount or the term. “Not advised” means asking for payment up front.
Visible after signing inVisible after signing in
Credit check for an amount and term of your choice
Name hiddenVisible after signing in appointed as director
Legal-form conversion: from private limited company (pre-2019) to private limited company · General meeting of 19-10-2021 · Gazette deed
Merger: CLINIPHAR takes over CLININVEST
“Het onroerend en roerend vermogen dat zij door inbreng,aankoop of anderszins zal…” (deed in Dutch) · The company holds all the shares of CLININVEST · General meeting of 16-12-2011 · Gazette deed
Merger proposal: CLINIPHAR takes over CLININVEST
Capital €18,600, annual accounts 2011 · Gazette deed
Sector peers are the companies with the same activity (NACE code) and, where stated, the same size, that the company is compared with. A percentile says how many of them do worse.
These companies have the same main activity as CLINIPHAR: medical imaging and medical laboratories (NACE 86910). They are comparable in size and age: total assets between €1.6m and €3.6m, founded between 1990 and 2006.
The company number of CLINIPHAR is 0473.637.637. The VAT number is the same number with BE in front: BE 0473.637.637.
Where is CLINIPHAR based?
The registered office is at Kempervendreef 17, 3140 Keerbergen.Company details
What does CLINIPHAR do?
According to the KBO register, the main activity is medical imaging and medical laboratories (NACE 86910).
What is the legal form of CLINIPHAR?
CLINIPHAR is a private limited company (BV).
When was CLINIPHAR founded?
CLINIPHAR was founded on 28-12-2000.
Is CLINIPHAR still active?
Yes, CLINIPHAR is an active enterprise in the KBO register.
What is the turnover of CLINIPHAR?
The turnover in financial year 2025 is ≈ €330,000. This figure is estimated from the gross margin of €165,604 and 40 comparable companies (NACE 86). It probably lies between €280,000 and €460,000.Financials
Is CLINIPHAR profitable?
In financial year 2025, CLINIPHAR made a profit of €65,315.
Where can I find the annual accounts of CLINIPHAR?
CLINIPHAR filed 25 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of CLINIPHAR due?
CLINIPHAR must file the annual accounts for financial year 2026 by 31-07-2027.Timeline